ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists the ReCLAIM-2 study of elamipretide as completed. The randomized, double-masked, placebo-controlled trial evaluated safety, efficacy and pharmacokinetics in people with age-related macular degeneration and non-central geographic atrophy; the excerpt provides no results.
- 01The registry reports the study status as completed.
- 02The trial compared elamipretide with placebo using a randomized, double-masked design.
- 03No safety, efficacy or pharmacokinetic findings are included in the excerpt.
Why it matters Editorial
The listing documents a completed clinical evaluation of elamipretide, but the excerpt does not establish its safety or efficacy.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide